Grant ID

02T-233

Illness

Schizophrenia

Primary Drug/Intervention

Entacapone

Primary Dosage

600 bid

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Klein

Sample Size

80

Duration of Study Period for Each Subject

12 weeks

Outcome Measurements

PANSS, Treatment Emergent Symptom Scale, Cognitive Battery

Results

Fifty patients were randomized and 45 completed the study. There was no significant difference between entacapone and placebo on ratings of psychiatric symptoms or quality of life. Patients treated with entacapone had a greater improvement in immediate memory than did placebo-treated group (about a 10% change). It is not clear that this cognitive effect is clinically meaningful.

Publication

N/A

Link

N/A

PI Name

Ehud Klein

Degree

MD

Center

Rambam Medical Center & B. Rappaport Faculty of Medicine, Technion, IIT

Institution

Rambam Medical Center, Dept. of Psychiatry

Address

City or Town

Haifa

State or Province

N/A

Zip or Postal Code

31096

Country

Israel

Email Address

e_klein@rambam.health.gov.il